A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

NCT01950364 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma
Anaplastic Large-cell Lymphoma

Interventions

DRUG: brentuximab vedotin
DRUG: Brentuximab vedotin and rifampicin

Sponsor

Millennium Pharmaceuticals, Inc.